Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 109 Next >>

Filter Applied: safety (Click to remove)

Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025

Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke 51:1616-1619, Beharry, J.,et al, 2020

Stroke Outcomes with use of Antithrombotics within 24 hours after Recanalization Treatment
Neurol 87:996-1002, Jeong, H.G.,et al, 2016

Vitamin K Antagonists and Risk of Subdural Hematoma
Stroke 45:1672-1678, Connolly, B.J.,et al, 2014

Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013

Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013

Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012

Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012

Antithrombotic Therapy and Bleeding Risk in a Prospective Cohort Study of Patients with Cerebral Cavernous Malformations
Stroke 43:3196-3199, Schneble, H.,et al, 2012

Bleeding During Treatment with Aspirin Versus Apixaban in Patients with Atrial Fibrillation Unsuitable for Warfarin
Stroke 43:3291-3297, Flaker, G.,et al, 2012

Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009

Combining Aspirin With Oral Anticoagulant Therapy: Is This a Safe and Effective Practice in Patients With Atrial Fibrillation?
Stroke 38:1652-1654, Gorelick,P.B., 2007

Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007

A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
NEJM 394:442-450, Ryan,S.J.,et al, 2026

Safety and Outcomes of Dibigatran Reversal with Idarucizumab Before IV Thrombolysis in Patients with Acute Ischemic Stroke
Neurol 106:e218012, Saflund,M.,et al, 2026

Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025

Endovascular Thrombectomy Versus Best Medical Therapy for Large Vessel Occlusion Stroke Beyond 24 Hours: A Systematic Review and Meta-Analysis
Stroke 56:3127-3137, Rodriguez-Caliemnes,A.,et al, 2025

Mechanical Thrombectomy in Anticoagulated Patients with Acute Ischemic Stroke, A Meta-Analysis
Neurologist 29:194-203, Zhang,H.L.,et al, 2024

Intravenous Thrombolysis in Patients with Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
JAMA Neurol 80:233-243, 231, Meinel,T.R.,et al, 2023

Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion
NEJM 388:2025-2095, Zi,W.,et al, 2023

Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023

Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023

Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation
Ann Neurol 91:78-88, Polymeris, A.A.,et al, 2022

Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022

Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022

Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021

Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021

Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021

Clinical Outcomes in Atrial Fibrillation Patients with a History of Cancer Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 52:3132-3141, Chan, Y.H.,et al, 2021

Caudal Epidural Steroid Injections in the Setting of Remaining on Antithrombotics: A Retrospective Study
Pain Physician 24:e821-e828, Simon,J.I.,et al, 2021

Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants
Stroke 51:533-541, Shahjouei, S.,et al, 2020

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
NEJM 382:1599-1607,1650, Agnelli, G.,et al, 2020

Stroke Reperfusion Therapy Following Dabigatran Reversal with Idarucizumab in a National Cohort
Neurol 94:e1968-e1972, Barber, P.A.,et al, 2020

Antiplatelet and Anticoagulant Risk for Select Spine Interventions:A Retrospective Cohort
Pain Med 21:910-917, Ehsanian,R.,et al, 2020

Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage
Stroke 50:529-536, Bower, M.M.,et al, 2019

Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared with Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke
JAMA Neurol 76:774-782, Tillman, H.,et al, 2019

Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019

Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019

Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019

Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019

Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
NEJM 379:215-225, 291, Johnston, S.C.,et al, 2018

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
NEJM 378:2191-2201, Hart, R.G.,et al, 2018

Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018

Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018

Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018

Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018

Safety of Lumbar Puncture Performed on Dual Antiplatelet Therapy
Mayo Clin Proc 93:627-629, Carabenciov,I.D.,et al, 2018

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017



Showing articles 0 to 50 of 109 Next >>